Mundipharma International (Mundipharma) has unveiled four abstracts from UK health economic studies in the respiratory, analgesic and oncology portfolios at the European Congress of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR).
The new data shows that a number of key products within its network of independent associated companies’ portfolio, offer superior or comparable efficacy and value for money compared with existing standards of care.
Mundipharma chief marketing officer Georg Toufar said the company recognises the current economic environment and resulting budget constraints for healthcare systems.
"As these studies show, our value proposition is aligned with the payer priority, providing patients access to better health care solutions while limiting clinical and financial risk exposure for the payer," Toufar said.
According to the first study, the economic costs of asthma are among the highest for non-communicable diseases (NCDs) due to the use of substantial health services in many cases over a lifetime.
Analysis is based on assumption of the use of similar levels of inhaled corticosteroid (ICS) with two fixed-dose combination regimens.
The study estimated the budget impact of using a fixed-dose combination inhaler of fluticasone propionate and formoterol fumarate (flutiform) as an alternative to fluticasone propionate and salmeterol xinafoate (Seretide Evohaler) in adult asthma patients, for an average NHS clinical commissioning group (CCG) in England.
Annual drug acquisition costs per person were discovered to be lower with flutiform compared with Seretide Evohaler.
The second study which is aimed at assessing ‘the potential of a reduction in the risk of opioid-related fractures to drive the cost-effectiveness of an analgesic’ reported that an increased risk of fractures has been observed in patients treated with opiates, possibly resulting from falls related to the central nervous system effects like dizziness.
The study is designed to explore whether transdermal buprenorphine (BuTrans 5µg/h, 10µg/h and 20µg/h Transdermal Patch) has the potential to be cost effective due to a reduced risk for fracture.
In the third study, the quality of life benefits and cost impact of prolonged release oxycodone hydrochloride/naloxone hydrochloride (Targinact) in patients with moderate to severe pain and opioid-induced constipation (OIC) were assessed.
Evaluated in the fourth study was the cost-effectiveness of bendamustine hydrochloride (Levact) given with rituximab (B-R), compared with standard of care in the first-line treatment of patients with advanced indolent non-Hodgkin’s lymphoma (iNHL) in England and Wales.
All studies are part of the company’s effort to improve patient experience and clinical outcomes.
Mundipharma head of market access Francois Bernard said the company’s value proposition comes with a built-in ‘insurance policy’ for payers.
"We choose to work with molecules for which the medical concepts are already well proven; they have well-established safety and tolerability profiles; clearly defined patient populations, and deliver positive health outcomes," Bernard said.
"We then share this value with payers, minimising uncertainty around the impact on their budgets and patient outcomes."